IBRX | Ticker Profile - Titan Protect

IBRX

ImmunityBio, Inc.

Healthcare · Biotechnology · NMS

$6.92

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$8.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

75.14

Based on estimated future earnings — lower means cheaper

Rev Growth

+167.6%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$13.50

+95% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About ImmunityBio, Inc.

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

https://immunitybio.com

Country: United States Employees: 684 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.582

Good returns relative to risk taken

Kelly Fraction

0.0171

Marginal edge — very small allocation suggested

Calmar Ratio

0.131

Drawdown risk outweighs the returns — higher risk profile

Annual Return

9.7%

Historical annualised return based on price data

Max Drawdown

-74.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.07

Very low correlation to market moves

52W High

$12.43

44% below the year high

52W Low

$1.95

255% above the year low

Avg Volume

19,174,396

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

34.2%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.85

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

6.67

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.24

Like current ratio but excludes inventory — stricter test

Gross Margin

99.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-157.9%

Profit from core operations before interest and tax

Free Cash Flow

$-193,704,624

Negative — the business is spending more than it generates

Revenue (TTM)

$141M

Total revenue over the last 12 months

Net Income

$-854,534,016

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$22.00

Target Median

$13.50

Target Low

$12.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go